CMS requires providers to confirm the medication is used for weight reduction along with ongoing lifestyle changes, and that the individual met one of the following when treatment started: BMI 35 BMI 30 with conditions like HFpEF, uncontrolled hypertension, or CKD (stage 3a+) BMI 27 with prediabetes or established cardiovascular disease (e.g., prior MI, stroke, PAD) One important note: this coverage will operate outside of typical Part D plans, so the approval process will look different
While this test does not replace thyroid monitoring, it provides actionable insights into your metabolic profile, helping PlexusDx tailor your GLP-1 protocol alongside your existing thyroid regimen
Patients who value established clinical evidence and are comfortable with self-injection may find weekly tirzepatide injections the most straightforward choice
La mayora de los pacientes recibieron tratamiento para la diabetes tipo 2
Call (858) 524-3059 to schedule your Semaglutide Weight Loss Injections consultation today